{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"3"}]}],"title":"Documented Engraftment Syndrome"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"7"}]}],"title":"No Documented Engraftment Syndrome"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Comparison of severity of GI toxicity between FRE carriers and FRE non-carriers per the grade of GI toxicity","groups":[{"description":"FRE Negative Participants","id":"OG000","title":"FRE Negative"},{"description":"FRE Positive Participants","id":"OG001","title":"FRE Positive"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Subject pre-transplant sample","reportingStatus":"POSTED","timeFrame":"Duration between Apheresis Consultation and Day +100","title":"Comparison of Severity of GI Toxicity Between FRE Carriers and FRE Non-carriers","type":"SECONDARY","unitOfMeasure":"Participants"}